Inventor · disambiguated record
Mark Wood
Also filed as: WOOD MARK · WOOD MARK CHRISTOPHER
15 granted patents·24 pending applications·387 citations·filing 2002–2025
92Inventor score
Files withARBUTUS BIOPHARMA CORP18PROTIVA BIOTHERAPEUTICS INC6GENEVANT SCIENCES GMBH5HEYES JAMES4CHAPLIN DAVID J1
Top patents by PatentIndex Score
39 records- 0197US9352042B2Trialkyl cationic lipids and methods of use thereofPROTIVA BIOTHERAPEUTICS INC·Filed 2013·Granted May 31, 2016·121 cites·21 claims
- 0297US8466122B2Trialkyl cationic lipids and methods of use thereofHEYES JAMES·Filed 2011·Granted Jun 18, 2013·203 cites·18 claims
- 0396US10561732B2Trialkyl cationic lipids and methods of use thereofARBUTUS BIOPHARMA CORP·Filed 2016·Granted Feb 18, 2020·13 cites·9 claims
- 0495US10077232B2Cyclic cationic lipids and methods of useHEYES JAMES·Filed 2011·Granted Sep 18, 2018·15 cites·30 claims
- 0592US12043833B2Targeted compositionsARBUTUS BIOPHARMA CORP·Filed 2022·Granted Jul 23, 2024·1 cites·18 claims
- 0691US11427823B2Targeted compositionsARBUTUS BIOPHARMA CORP·Filed 2018·Granted Aug 30, 2022·5 cites·16 claims
- 0791US9126966B2Cationic lipids and methods of use thereofMARTIN ALAN·Filed 2012·Granted Sep 8, 2015·13 cites·41 claims
- 0890US8865675B2Compositions and methods for silencing apolipoprotein BHEYES JAMES·Filed 2011·Granted Oct 21, 2014·12 cites·46 claims
- 0984US11395854B2Trialkyl cationic lipids and methods of use thereofARBUTUS BIOPHARMA CORP·Filed 2020·Granted Jul 26, 2022·1 cites·14 claims
- 1082US2025099594A1Targeted compositionsARBUTUS BIOPHARMA CORP·Filed 2024·Application pending·0 cites
- 1182US2025179496A1Targeted compositionsARBUTUS BIOPHARMA CORP·Filed 2024·Application pending·0 cites
- 1281US2024245784A1Targeted nucleic acid conjugate compositionsARBUTUS BIOPHARMA CORP·Filed 2024·Application pending·0 cites
- 1380US2023165973A1Compositions and methods for delivering messenger rnaARBUTUS BIOPHARMA CORP·Filed 2022·Application pending·0 cites
- 1476US2023109183A1Trialkyl cationic lipids and methods of use thereofARBUTUS BIOPHARMA CORP·Filed 2022·Application pending·0 cites
- 1573US2020297870A1Compositions and methods for delivering messenger rnaARBUTUS BIOPHARMA CORP·Filed 2020·Application pending·0 cites
- 1672US2025281422A1Cationic lipids containing siliconARBUTUS BIOPHARMA CORP·Filed 2025·Application pending·0 cites
- 1769US12350383B2Cationic lipids containing siliconARBUTUS BIOPHARMA CORP·Filed 2019·Granted Jul 8, 2025·0 cites·9 claims
- 1867US2025215042A1Mannose-targeted compositionsGENEVANT SCIENCES GMBH·Filed 2023·Application pending·0 cites
- 1967US2020282060A1Novel cationic lipids and methods of use thereofARBUTUS BIOPHARMA CORP·Filed 2020·Application pending·0 cites
- 2065US8198302B2Compositions and methods with enhanced therapeutic activityCHAPLIN DAVID J·Filed 2004·Granted Jun 12, 2012·3 cites·8 claims
- 2165US2025332112A1Ionizable cationic lipids for lipid nanoparticlesGENEVANT SCIENCES GMBH·Filed 2023·Application pending·0 cites
- 2263US2024148663A1Peg lipids and lipid nanoparticlesGENEVANT SCIENCES GMBH·Filed 2021·Application pending·0 cites
- 2363US2016151284A1Compositions and methods for delivering messenger rnaPROTIVA BIOTHERAPEUTICS INC·Filed 2014·Application pending·0 cites
- 2461US11896672B2Targeted nucleic acid conjugate compositionsARBUTUS BIOPHARMA CORP·Filed 2017·Granted Feb 13, 2024·0 cites·11 claims
- 2559US11013726B2Substituted pyridinone-containing trycyclic compounds, and methods using sameARBUTUS BIOPHARMA CORP·Filed 2020·Granted May 25, 2021·0 cites·27 claims
- 2659US2014288146A1Novel trialkyl cationic lipids and methods of use thereofPROTIVA BIOTHERAPEUTICS INC·Filed 2013·Application pending·0 cites
- 2757US2016256567A1Compositions and methods for delivering messenger rnaPROTIVA BIOTHERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 2857US2019106379A1Novel cyclic cationic lipids and methods of useARBUTUS BIOPHARMA CORP·Filed 2018·Application pending·0 cites
- 2957US2016256568A1Compositions and methods for delivering messenger rnaPROTIVA BIOTHERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 3056US10821103B2Substituted pyridinone-containing trycyclic compounds, and methods using sameARBUTUS BIOPHARMA CORP·Filed 2017·Granted Nov 3, 2020·0 cites·58 claims
- 3155US12357705B2Negatively charged peg-lipid conjugatesARBUTUS BIOPHARMA CORP·Filed 2019·Granted Jul 15, 2025·0 cites·20 claims
- 3255US2022387600A1Conjugates and methods for treating liver fibrosisGENEVANT SCIENCES GMBH·Filed 2020·Application pending·0 cites
- 3354US2022288214A1Conjugates and methods for treating acromegalyGENEVANT SCIENCES GMBH·Filed 2020·Application pending·0 cites
- 3450US2017151333A1Novel cationic lipids and methods of use thereofPROTIVA BIOTHERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 3550US2013123338A1Novel cationic lipids and methods of use thereofHEYES JAMES·Filed 2011·Application pending·0 cites
- 3648US2022174950A1Antifungal CompositionsUNIV EXETER·Filed 2020·Application pending·0 cites
- 3747US2003181531A1Compositions and methods of administering tubulin binding agents for the treatment of ocular diseasesFiled 2002·Application pending·0 cites
- 3846US2022062323A1Bivalent targeted conjugatesHOLLAND RICHARD J·Filed 2019·Application pending·0 cites
- 3942US2004229960A1Compositions and methods of administering tubulin binding agents for the treatment of ocular diseasesFiled 2003·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Mark Wood files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →